Rigel Pharmaceuticals
RIGL
138 hedge funds and large institutions have $334M invested in Rigel Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 50 reducing their positions, and 19 closing their positions.
26% more capital invested
Capital invested by funds: $265M → $334M (+$68.7M)
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
2% more funds holding
Funds holding: 135 → 138 (+3)
0.32% less ownership
Funds ownership: 8.6% → 8.27% (-0.32%)
28% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 50
42% less call options, than puts
Call options by funds: $980K | Put options by funds: $1.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$16.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.11M |
| 3 |
Morgan Stanley
New York
|
+$3.76M |
| 4 |
SGA
Sector Gamma AS
Oslo,
Norway
|
+$3.35M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$5.98M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$5.93M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$5.79M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.67M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$4.08M |
RIGL Hedge Fund Activity: Q3 2020 in Review
138 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2020, worth a combined $334M — up 26% from $265M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RIGL positions and 19 closed out — a net gain of 3 holders — while 36 added to existing stakes and 50 trimmed.
The largest buyer was State Street, adding an estimated $16.1M. The largest seller was Renaissance Technologies, cutting an estimated $5.98M.
- 138 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2020, up from 135 in Q2 2020.
- Funds reported $334M of Rigel Pharmaceuticals stock for Q3 2020, up 26% quarter-over-quarter.
- 22 funds opened new Rigel Pharmaceuticals positions in Q3 2020 and 19 closed out, a net change of +3 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2020 was State Street, an estimated $16.1M added.
- The largest Rigel Pharmaceuticals seller in Q3 2020 was Renaissance Technologies, an estimated $5.98M sold.
Based on aggregated 13F filings for Q3 2020.